Background: Two recent studies have provided opposite results on the efficacy of naltrexone on uremic pruritus. We have performed a third study. Objective: To compare the efficacy and tolerance of naltrexone and loratadine in uremic pruritus. Patients/Methods: Among 296 hemodialyzed patients, 65 suffered from uremic pruritus. Fifty-two patients participated in the study. The patients were treated for 2 weeks with naltrexone (50 mg/day; 26 patients) or loratadine (10 mg/day; 26 patients), after a washout of 48 h. Pruritus intensity was scored by a visual analogue scale (VAS). Adverse events were carefully searched for. The two groups were statistically equivalent. Results: There was no significant difference in the mean VAS scores after treatment, but naltrexone allowed a dramatic decrease in VAS scores (Δ >3/10) in 7 patients. Adverse events (mainly nausea and sleep disturbances) were observed in 10/26 patients. Conclusions: Naltrexone is effective only in a subset of patients. Adverse events are very frequent. The differences of efficacy and tolerance between patients might be due to metabolism. Naltrexone might be considered as a second-line treatment.

1.
Mettang T, Fischer F, Kuhlmann U: Urämischer Pruritus. Dtsch Med Wochenschr 1996;12:1025–1031.
2.
Stockenhuber F, Sunder-Plassmann G, Balcke P: Increased plasma histamine levels in chronic renal failure. N Engl J Med 1987;317:386.
3.
Kiichiro D, Nishiiura K, Tanaka M: Increased met-enkephalin plasma levels in hemodialysis patients with or without pruritus. J Dermatol Sci 1995;10:238–240.
4.
Mettang T, Pauli-Magnus C, Alscher D: Uraemic pruritus – New perspectives and insights from recent trials. Nephrol Dial Transplant 2002;17:1558–1563.
5.
Schwartz I, Iaina A: Management of uremic pruritus. Semin Dialysis 2000;13:177–180.
6.
Misery L, Cambazard F: Prurit (avec le traitement). Rev Prat 2002;52:1139–1144.
7.
Andersen L, Friedberg M, Lokkegaard N: Naloxone in treatment of uremic pruritus. Clin Nephrol 1985;21:355–356.
8.
Peer G, Kivity S, Agami O: Randomized cross-over trial of naltrexone in uremic pruritus. Lancet 1996;348:1552–1554.
9.
Pauli-Magnus C, Mikus G, Alscher D, et al: Naltrexone does not relieve uremic pruritus: Results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000;11:514–519.
10.
Urbonas A, Schwart R, Szepietowski J: Uremic pruritis – An update. Am J Nephrol 2001;21:343–350.
11.
Gilchrest BA, Stern RS, Steinmann TI: Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol 1982;118:154–156.
12.
Ponticelli C, Bencini PL: Uremic pruritus: A review. Nephron 1992;60:1–5.
13.
Giocoecha M, De Saquera P, Orchando A, et al: Uremic pruritus: An unresolved problem in hemodialysis patients. Nephron 1999;82:73–74.
14.
Kambia K, Bah S, Dine T, et al: High-performance liquid chromatographic determination of naltrexone in plasma of hemodialysis patients. Biomed Chromatogr 2000;14:151–155.
15.
Ferrari A, Bertolotti M, Dell’Utri A, et al: Serum time course of naltrexone and 6-beta-naltrexol levels during long-term treatment in drug addicts. Drug Alcohol Depend 1998;52:211–220.
16.
Stahle-Backdahl M: Stratum corneum hydratation in patients undergoing maintenance hemodialysis. Acta Derm Venereol 1988;68:531–534.
17.
Cho YL, Liu HN, Huang TP, Tarng DC: Uremic pruritus: Roles of parathyroid hormone and substance P. J Am Acad Dermatol 1997;36:538–543.
18.
Cohen EP, Russell TJ, Garancis JC: Mast cell and calcium in severe uremic pruritus. Am J Med Sci 1992;303:360–365.
19.
Thomas PK, Hollinrake K, Lascelles RG: The polyneuropathy of chronic renal failure. Brain 1971;94:761–780.
20.
Fantini F, Baraldi A, Sevignani C: Cutaneous innervation in chronic renal failure patients. Acta Derm Venereol 1992;72:102–105.
21.
Mettang T, Fritz P, Weber J: Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD): The role of plasma histamine and skin mast cells. Clin Nephrol 1990;34:136–141.
22.
Balaskas EV, Bamihas GI, Karamouzis M, et al: Histamine and serotonin in uremic pruritus: Effect of ondansetron in CAPD-pruritic patients. Nephron 1998;78:395–402.
23.
Ashmore SD, Jones CH, Newstead CG, et al: Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000;35:827–831.
24.
Reiz S, Westberg M: Side effects of epidural morphine. Lancet 1980;ii:203–204.
25.
Mettang T, Fischer FP, Dollenbacher U, Kuhlmann U: Uremic pruritus is not related to beta-endorphin serum levels in hemodialysis. Nephrol Dial Transplant 1998;13:231–232.
26.
Charlesworth EN, Beltrani VS: Pruritic dermatoses: Overview of etiology and therapy. Am J Med 2002;113:25S–33S.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.